Parkinson's dementia

From Aaushi
Jump to navigation Jump to search

Etiology

  • may be same disorder as Lewy body dementia differing in presentation, rather than in etiology or pathology[3]

Epidemiology

Clinical manifestations

Differential diagnosis

Management

More general terms

Additional terms

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  2. 2.0 2.1 Journal Watch 25(1):11, 2005 Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2509-18. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15590953
  3. 3.0 3.1 McKeith I. Dementia with Lewy bodies and Parkinson's disease with dementia: Where two worlds collide Pract Neurol 2007, 7:374 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18024777
  4. Prescriber's Letter 16(4): 2009 Parkinson's Dementia and Lewy Body Dementia Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250407&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 Emre M et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 Oct; 9:969 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20729148
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Wang HF et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2014 May 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24828899
  7. 7.0 7.1 Weintraub D, Hauser RA, Elm JJ et al Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 May;31(5):709-14. Epub 2016 Mar 31. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27030249
  8. 8.0 8.1 Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230-1238 PMID: https://www.ncbi.nlm.nih.gov/pubmed/2291544
  9. 9.0 9.1 Mantri S, Fullard M, Gray SL et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease. JAMA Neurol 2018 Oct 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/3028504 https://jamanetwork.com/journals/jamaneurology/fullarticle/2704469
  10. 10.0 10.1 Espay AJ et al. Rivastigmine in Parkinson's disease dementia with orthostatic hypotension. Ann Neurol 2020 Oct 5; PMID: https://www.ncbi.nlm.nih.gov/pubmed/33016374 https://onlinelibrary.wiley.com/doi/10.1002/ana.25923
  11. 11.0 11.1 Kim R, Park S, Yoo D et al. on Association of physical activity and APOE genotype with longitudinal cognitive change in early PD. Neurology 2021 Mar 31; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/33790041 https://n.neurology.org/content/early/2021/03/31/WNL.0000000000011852
  12. 12.0 12.1 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
    Lenka A, Pagonabarraga J, Pal PK et al. Minor hallucinations in Parkinson disease: A subtle symptom with major clinical implications. Neurology. 2019;93(6):259-266 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31289146 PMCID: PMC6709995 Free PMC article https://n.neurology.org/content/93/6/259